Enliven Therapeutics (ELVN) Income from Continuing Operations (2019 - 2026)
Enliven Therapeutics (ELVN) posted Income from Continuing Operations of 27927000.0 for Q1 2026, up 18.82% sequentially from 34402000.0 in Q4 2025, and up 12.11% YoY from 24909708.13 in Q1 2025.
Enliven Therapeutics (ELVN) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Enliven Therapeutics has reported Income from Continuing Operations for 8 years, with the latest figure at 27927000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 12.11% year-over-year to 27927000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 117137000.0 (down 5.73% YoY) and the FY2025 annual result came in at 147462000.0, up 15.24% from the prior year.
- Income from Continuing Operations advanced to 27927000.0 in Q1 2026 per ELVN's latest filing, from 34402000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 8897000.0 in Q1 2022 and troughed at 65515000.0 in Q4 2023.
- A 5-year average of 25890647.06 and a median of 26072000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations sank 120.49% in 2023, then jumped 58.88% in 2024.
- Over 5 years, Income from Continuing Operations stood at 29714000.0 in 2022, then slumped by 120.49% to 65515000.0 in 2023, then surged by 58.88% to 26940000.0 in 2024, then decreased by 27.7% to 34402000.0 in 2025, then rose by 18.82% to 27927000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 27927000.0, 34402000.0, and 25610000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Enliven Therapeutics | 4.31 Bn | 3.41 Bn | - | -39.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -39.12 Mn |
| Mar 31, 2026 | -27.93 Mn |
| Dec 31, 2025 | -34.40 Mn |
| Sep 30, 2025 | -25.61 Mn |
| Jun 30, 2025 | -29.20 Mn |
| Mar 31, 2025 | -31.78 Mn |
| Dec 31, 2024 | -26.94 Mn |
| Sep 30, 2024 | -27.15 Mn |
| Jun 30, 2024 | -24.92 Mn |
| Mar 31, 2024 | -26.07 Mn |
| Dec 31, 2023 | -65.52 Mn |
| Sep 30, 2023 | -24.67 Mn |
| Jun 30, 2023 | -20.25 Mn |
| Mar 31, 2023 | -16.44 Mn |
| Dec 31, 2022 | -29.71 Mn |
| Sep 30, 2022 | -11.20 Mn |
| Jun 30, 2022 | -9.46 Mn |
| Mar 31, 2022 | -8.90 Mn |
| Dec 31, 2021 | -14.38 Mn |
| Sep 30, 2021 | -13.91 Mn |